Cantor Fitzgerald initiates TrovaGene (TROV) at Buy with a $10 price target citing the...

|By:, SA News Editor

Cantor Fitzgerald initiates TrovaGene (TROV) at Buy with a $10 price target citing the likelihood that "compelling early data associated with the company's nucleic acid assays … will increase interest among leading cancer centers in further exploring the clinical utility" of complementing or replacing tumor tissue biopsies.